Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches

doi:10.5411/wji.v5.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14534)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

891

WORD

392

HTML

7939

Figures (1-1)

272

Tables (1-4)

324

Sum=9818

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

758

Download

1693

Sum=2451

Publishing Process of This Article

Item

Count

Browse

1147

Download

1118

Sum=2265

Mar 27, 2015 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Immunology

ISSN

2219-2824

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Immunol. Mar 27, 2015; 5(1): 1-15
Published online Mar 27, 2015. doi: 10.5411/wji.v5.i1.1

Table 4 Clinical study outcomes of combination chemotherapy and immune checkpoint blockade

Ref.	Phase	Cancer type	Treatment combination	Outcome
Robert et al[70]	3	Melanoma	Ipilimumab + dacarbazine	3-yr survival 20.8% (P < 0.001)
Lynch et al[94]	2	NSCLC	Ipilimumab + paclitaxel, carboplatin (phased)	irPFS HR: 0.72, P = 0.05
Reck et al[^95]	2	SCLC	Ipilimumab + paclitaxel, carboplatin (phased)	irPFS HR: 0.64, P = 0.03
Hersh et al[90]	2	Melanoma	Ipilimumab + dacarbazine	ORR: 14.3% (95%CI: 4.8-30.3)

All outcomes are in combination therapy treatment arms. NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; irPFS: Immune-related progression free survival; HR: hazard ratio; ORR: Objective response rate.

Citation: Patel MA, Kim JE, Ruzevick J, Lim M. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol 2015; 5(1): 1-15
URL: https://www.wjgnet.com/2219-2824/full/v5/i1/1.htm
DOI: https://dx.doi.org/10.5411/wji.v5.i1.1